The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Varicella Attenuated Live Vaccine-Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2030
Synopsis
A live attenuated varicella vaccine, derived from the Oka strain of VZV has clinical efficacy for the prevention of varicella.
The global market for Varicella Attenuated Live Vaccine was estimated to be worth US$ 2553.6 million in 2023 and is forecast to a readjusted size of US$ 3440.8 million by 2030 with a CAGR of 4.3% during the forecast period 2024-2030
For the major players of Varicella Attenuated Live Vaccine, Merck maintained its first place in the ranking in 2019, followed by BCHT, Shanghai Institute, GSK and Keygen. Top 5 players accounted for about 95% of the Global Varicella Attenuated Live Vaccine revenue market share in 2019.
The sales market for Varicella Attenuated Live Vaccine was divided into five geographic regions. Asia-Pacific occupied the largest sales market share with about 58% in 2019. It is followed by North America and Europe with about 18% and about 13% respectively, while other regions have smaller market.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Varicella Attenuated Live Vaccine, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Varicella Attenuated Live Vaccine by region & country, by Type, and by Application.
The Varicella Attenuated Live Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Doses) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Varicella Attenuated Live Vaccine.
Market Segmentation
By Company
Merck
BCHT
Shanghai Institute
GSK
Keygen
Green Cross
Biken
Shanghai Rongsheng Biotech
Changchun Changsheng Life Sciences Limited
Segment by Type:
Monovalent Vaccine
Combination Vaccine
Segment by Application
Kids Injection
Adults Injection
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Varicella Attenuated Live Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Varicella Attenuated Live Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Varicella Attenuated Live Vaccine in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
A live attenuated varicella vaccine, derived from the Oka strain of VZV has clinical efficacy for the prevention of varicella.
The global market for Varicella Attenuated Live Vaccine was estimated to be worth US$ 2553.6 million in 2023 and is forecast to a readjusted size of US$ 3440.8 million by 2030 with a CAGR of 4.3% during the forecast period 2024-2030
For the major players of Varicella Attenuated Live Vaccine, Merck maintained its first place in the ranking in 2019, followed by BCHT, Shanghai Institute, GSK and Keygen. Top 5 players accounted for about 95% of the Global Varicella Attenuated Live Vaccine revenue market share in 2019.
The sales market for Varicella Attenuated Live Vaccine was divided into five geographic regions. Asia-Pacific occupied the largest sales market share with about 58% in 2019. It is followed by North America and Europe with about 18% and about 13% respectively, while other regions have smaller market.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Varicella Attenuated Live Vaccine, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Varicella Attenuated Live Vaccine by region & country, by Type, and by Application.
The Varicella Attenuated Live Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Doses) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Varicella Attenuated Live Vaccine.
Market Segmentation
By Company
Merck
BCHT
Shanghai Institute
GSK
Keygen
Green Cross
Biken
Shanghai Rongsheng Biotech
Changchun Changsheng Life Sciences Limited
Segment by Type:
Monovalent Vaccine
Combination Vaccine
Segment by Application
Kids Injection
Adults Injection
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Varicella Attenuated Live Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Varicella Attenuated Live Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Varicella Attenuated Live Vaccine in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Index1 Market Overview
1.1 Varicella Attenuated Live Vaccine Product Introduction
1.2 Global Varicella Attenuated Live Vaccine Market Size Forecast
1.2.1 Global Varicella Attenuated Live Vaccine Sales Value (2019-2030)
1.2.2 Global Varicella Attenuated Live Vaccine Sales Volume (2019-2030)
1.2.3 Global Varicella Attenuated Live Vaccine Sales Price (2019-2030)
1.3 Varicella Attenuated Live Vaccine Market Trends & Drivers
1.3.1 Varicella Attenuated Live Vaccine Industry Trends
1.3.2 Varicella Attenuated Live Vaccine Market Drivers & Opportunity
1.3.3 Varicella Attenuated Live Vaccine Market Challenges
1.3.4 Varicella Attenuated Live Vaccine Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Varicella Attenuated Live Vaccine Players Revenue Ranking (2023)
2.2 Global Varicella Attenuated Live Vaccine Revenue by Company (2019-2024)
2.3 Global Varicella Attenuated Live Vaccine Players Sales Volume Ranking (2023)
2.4 Global Varicella Attenuated Live Vaccine Sales Volume by Company Players (2019-2024)
2.5 Global Varicella Attenuated Live Vaccine Average Price by Company (2019-2024)
2.6 Key Manufacturers Varicella Attenuated Live Vaccine Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Varicella Attenuated Live Vaccine Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Varicella Attenuated Live Vaccine
2.9 Varicella Attenuated Live Vaccine Market Competitive Analysis
2.9.1 Varicella Attenuated Live Vaccine Market Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Varicella Attenuated Live Vaccine Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Varicella Attenuated Live Vaccine as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Monovalent Vaccine
3.1.2 Combination Vaccine
3.2 Global Varicella Attenuated Live Vaccine Sales Value by Type
3.2.1 Global Varicella Attenuated Live Vaccine Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Varicella Attenuated Live Vaccine Sales Value, by Type (2019-2030)
3.2.3 Global Varicella Attenuated Live Vaccine Sales Value, by Type (%) (2019-2030)
3.3 Global Varicella Attenuated Live Vaccine Sales Volume by Type
3.3.1 Global Varicella Attenuated Live Vaccine Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Varicella Attenuated Live Vaccine Sales Volume, by Type (2019-2030)
3.3.3 Global Varicella Attenuated Live Vaccine Sales Volume, by Type (%) (2019-2030)
3.4 Global Varicella Attenuated Live Vaccine Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Kids Injection
4.1.2 Adults Injection
4.2 Global Varicella Attenuated Live Vaccine Sales Value by Application
4.2.1 Global Varicella Attenuated Live Vaccine Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Varicella Attenuated Live Vaccine Sales Value, by Application (2019-2030)
4.2.3 Global Varicella Attenuated Live Vaccine Sales Value, by Application (%) (2019-2030)
4.3 Global Varicella Attenuated Live Vaccine Sales Volume by Application
4.3.1 Global Varicella Attenuated Live Vaccine Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Varicella Attenuated Live Vaccine Sales Volume, by Application (2019-2030)
4.3.3 Global Varicella Attenuated Live Vaccine Sales Volume, by Application (%) (2019-2030)
4.4 Global Varicella Attenuated Live Vaccine Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Varicella Attenuated Live Vaccine Sales Value by Region
5.1.1 Global Varicella Attenuated Live Vaccine Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Varicella Attenuated Live Vaccine Sales Value by Region (2019-2024)
5.1.3 Global Varicella Attenuated Live Vaccine Sales Value by Region (2025-2030)
5.1.4 Global Varicella Attenuated Live Vaccine Sales Value by Region (%), (2019-2030)
5.2 Global Varicella Attenuated Live Vaccine Sales Volume by Region
5.2.1 Global Varicella Attenuated Live Vaccine Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Varicella Attenuated Live Vaccine Sales Volume by Region (2019-2024)
5.2.3 Global Varicella Attenuated Live Vaccine Sales Volume by Region (2025-2030)
5.2.4 Global Varicella Attenuated Live Vaccine Sales Volume by Region (%), (2019-2030)
5.3 Global Varicella Attenuated Live Vaccine Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Varicella Attenuated Live Vaccine Sales Value, 2019-2030
5.4.2 North America Varicella Attenuated Live Vaccine Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Varicella Attenuated Live Vaccine Sales Value, 2019-2030
5.5.2 Europe Varicella Attenuated Live Vaccine Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Varicella Attenuated Live Vaccine Sales Value, 2019-2030
5.6.2 Asia Pacific Varicella Attenuated Live Vaccine Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Varicella Attenuated Live Vaccine Sales Value, 2019-2030
5.7.2 South America Varicella Attenuated Live Vaccine Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Varicella Attenuated Live Vaccine Sales Value, 2019-2030
5.8.2 Middle East & Africa Varicella Attenuated Live Vaccine Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Varicella Attenuated Live Vaccine Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Varicella Attenuated Live Vaccine Sales Value
6.2.1 Key Countries/Regions Varicella Attenuated Live Vaccine Sales Value, 2019-2030
6.2.2 Key Countries/Regions Varicella Attenuated Live Vaccine Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Varicella Attenuated Live Vaccine Sales Value, 2019-2030
6.3.2 United States Varicella Attenuated Live Vaccine Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Varicella Attenuated Live Vaccine Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Varicella Attenuated Live Vaccine Sales Value, 2019-2030
6.4.2 Europe Varicella Attenuated Live Vaccine Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Varicella Attenuated Live Vaccine Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Varicella Attenuated Live Vaccine Sales Value, 2019-2030
6.5.2 China Varicella Attenuated Live Vaccine Sales Value by Type (%), 2023 VS 2030
6.5.3 China Varicella Attenuated Live Vaccine Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Varicella Attenuated Live Vaccine Sales Value, 2019-2030
6.6.2 Japan Varicella Attenuated Live Vaccine Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Varicella Attenuated Live Vaccine Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Varicella Attenuated Live Vaccine Sales Value, 2019-2030
6.7.2 South Korea Varicella Attenuated Live Vaccine Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Varicella Attenuated Live Vaccine Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Varicella Attenuated Live Vaccine Sales Value, 2019-2030
6.8.2 Southeast Asia Varicella Attenuated Live Vaccine Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Varicella Attenuated Live Vaccine Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Varicella Attenuated Live Vaccine Sales Value, 2019-2030
6.9.2 India Varicella Attenuated Live Vaccine Sales Value by Type (%), 2023 VS 2030
6.9.3 India Varicella Attenuated Live Vaccine Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Merck
7.1.1 Merck Company Information
7.1.2 Merck Introduction and Business Overview
7.1.3 Merck Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Merck Varicella Attenuated Live Vaccine Product Offerings
7.1.5 Merck Recent Development
7.2 BCHT
7.2.1 BCHT Company Information
7.2.2 BCHT Introduction and Business Overview
7.2.3 BCHT Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.2.4 BCHT Varicella Attenuated Live Vaccine Product Offerings
7.2.5 BCHT Recent Development
7.3 Shanghai Institute
7.3.1 Shanghai Institute Company Information
7.3.2 Shanghai Institute Introduction and Business Overview
7.3.3 Shanghai Institute Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Shanghai Institute Varicella Attenuated Live Vaccine Product Offerings
7.3.5 Shanghai Institute Recent Development
7.4 GSK
7.4.1 GSK Company Information
7.4.2 GSK Introduction and Business Overview
7.4.3 GSK Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.4.4 GSK Varicella Attenuated Live Vaccine Product Offerings
7.4.5 GSK Recent Development
7.5 Keygen
7.5.1 Keygen Company Information
7.5.2 Keygen Introduction and Business Overview
7.5.3 Keygen Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.5.4 Keygen Varicella Attenuated Live Vaccine Product Offerings
7.5.5 Keygen Recent Development
7.6 Green Cross
7.6.1 Green Cross Company Information
7.6.2 Green Cross Introduction and Business Overview
7.6.3 Green Cross Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.6.4 Green Cross Varicella Attenuated Live Vaccine Product Offerings
7.6.5 Green Cross Recent Development
7.7 Biken
7.7.1 Biken Company Information
7.7.2 Biken Introduction and Business Overview
7.7.3 Biken Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.7.4 Biken Varicella Attenuated Live Vaccine Product Offerings
7.7.5 Biken Recent Development
7.8 Shanghai Rongsheng Biotech
7.8.1 Shanghai Rongsheng Biotech Company Information
7.8.2 Shanghai Rongsheng Biotech Introduction and Business Overview
7.8.3 Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.8.4 Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccine Product Offerings
7.8.5 Shanghai Rongsheng Biotech Recent Development
7.9 Changchun Changsheng Life Sciences Limited
7.9.1 Changchun Changsheng Life Sciences Limited Company Information
7.9.2 Changchun Changsheng Life Sciences Limited Introduction and Business Overview
7.9.3 Changchun Changsheng Life Sciences Limited Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.9.4 Changchun Changsheng Life Sciences Limited Varicella Attenuated Live Vaccine Product Offerings
7.9.5 Changchun Changsheng Life Sciences Limited Recent Development
8 Industry Chain Analysis
8.1 Varicella Attenuated Live Vaccine Industrial Chain
8.2 Varicella Attenuated Live Vaccine Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Varicella Attenuated Live Vaccine Sales Model
8.5.2 Sales Channel
8.5.3 Varicella Attenuated Live Vaccine Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
List of TablesList of Tables
Table 1. Varicella Attenuated Live Vaccine Market Trends
Table 2. Varicella Attenuated Live Vaccine Market Drivers & Opportunity
Table 3. Varicella Attenuated Live Vaccine Market Challenges
Table 4. Varicella Attenuated Live Vaccine Market Restraints
Table 5. Global Varicella Attenuated Live Vaccine Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Varicella Attenuated Live Vaccine Revenue Market Share by Company (2019-2024)
Table 7. Global Varicella Attenuated Live Vaccine Sales Volume by Company (2019-2024) & (K Doses)
Table 8. Global Varicella Attenuated Live Vaccine Sales Volume Market Share by Company (2019-2024)
Table 9. Global Market Varicella Attenuated Live Vaccine Price by Company (2019-2024) & (USD/Dose)
Table 10. Key Manufacturers Varicella Attenuated Live Vaccine Manufacturing Base Distribution and Headquarters
Table 11. Key Manufacturers Varicella Attenuated Live Vaccine Product Type
Table 12. Key Manufacturers Time to Begin Mass Production of Varicella Attenuated Live Vaccine
Table 13. Global Varicella Attenuated Live Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Varicella Attenuated Live Vaccine as of 2023)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Global Varicella Attenuated Live Vaccine Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 17. Global Varicella Attenuated Live Vaccine Sales Value by Type (2019-2024) & (US$ Million)
Table 18. Global Varicella Attenuated Live Vaccine Sales Value by Type (2025-2030) & (US$ Million)
Table 19. Global Varicella Attenuated Live Vaccine Sales Market Share in Value by Type (2019-2024) & (%)
Table 20. Global Varicella Attenuated Live Vaccine Sales Market Share in Value by Type (2025-2030) & (%)
Table 21. Global Varicella Attenuated Live Vaccine Sales Volume by Type: 2019 VS 2023 VS 2030 (K Doses)
Table 22. Global Varicella Attenuated Live Vaccine Sales Volume by Type (2019-2024) & (K Doses)
Table 23. Global Varicella Attenuated Live Vaccine Sales Volume by Type (2025-2030) & (K Doses)
Table 24. Global Varicella Attenuated Live Vaccine Sales Market Share in Volume by Type (2019-2024) & (%)
Table 25. Global Varicella Attenuated Live Vaccine Sales Market Share in Volume by Type (2025-2030) & (%)
Table 26. Global Varicella Attenuated Live Vaccine Price by Type (2019-2024) & (USD/Dose)
Table 27. Global Varicella Attenuated Live Vaccine Price by Type (2025-2030) & (USD/Dose)
Table 28. Global Varicella Attenuated Live Vaccine Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 29. Global Varicella Attenuated Live Vaccine Sales Value by Application (2019-2024) & (US$ Million)
Table 30. Global Varicella Attenuated Live Vaccine Sales Value by Application (2025-2030) & (US$ Million)
Table 31. Global Varicella Attenuated Live Vaccine Sales Market Share in Value by Application (2019-2024) & (%)
Table 32. Global Varicella Attenuated Live Vaccine Sales Market Share in Value by Application (2025-2030) & (%)
Table 33. Global Varicella Attenuated Live Vaccine Sales Volume by Application: 2019 VS 2023 VS 2030 (K Doses)
Table 34. Global Varicella Attenuated Live Vaccine Sales Volume by Application (2019-2024) & (K Doses)
Table 35. Global Varicella Attenuated Live Vaccine Sales Volume by Application (2025-2030) & (K Doses)
Table 36. Global Varicella Attenuated Live Vaccine Sales Market Share in Volume by Application (2019-2024) & (%)
Table 37. Global Varicella Attenuated Live Vaccine Sales Market Share in Volume by Application (2025-2030) & (%)
Table 38. Global Varicella Attenuated Live Vaccine Price by Application (2019-2024) & (USD/Dose)
Table 39. Global Varicella Attenuated Live Vaccine Price by Application (2025-2030) & (USD/Dose)
Table 40. Global Varicella Attenuated Live Vaccine Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Global Varicella Attenuated Live Vaccine Sales Value by Region (2019-2024) & (US$ Million)
Table 42. Global Varicella Attenuated Live Vaccine Sales Value by Region (2025-2030) & (US$ Million)
Table 43. Global Varicella Attenuated Live Vaccine Sales Value by Region (2019-2024) & (%)
Table 44. Global Varicella Attenuated Live Vaccine Sales Value by Region (2025-2030) & (%)
Table 45. Global Varicella Attenuated Live Vaccine Sales Volume by Region (K Doses): 2019 VS 2023 VS 2030
Table 46. Global Varicella Attenuated Live Vaccine Sales Volume by Region (2019-2024) & (K Doses)
Table 47. Global Varicella Attenuated Live Vaccine Sales Volume by Region (2025-2030) & (K Doses)
Table 48. Global Varicella Attenuated Live Vaccine Sales Volume by Region (2019-2024) & (%)
Table 49. Global Varicella Attenuated Live Vaccine Sales Volume by Region (2025-2030) & (%)
Table 50. Global Varicella Attenuated Live Vaccine Average Price by Region (2019-2024) & (USD/Dose)
Table 51. Global Varicella Attenuated Live Vaccine Average Price by Region (2025-2030) & (USD/Dose)
Table 52. Key Countries/Regions Varicella Attenuated Live Vaccine Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 53. Key Countries/Regions Varicella Attenuated Live Vaccine Sales Value, (2019-2024) & (US$ Million)
Table 54. Key Countries/Regions Varicella Attenuated Live Vaccine Sales Value, (2025-2030) & (US$ Million)
Table 55. Key Countries/Regions Varicella Attenuated Live Vaccine Sales Volume, (2019-2024) & (K Doses)
Table 56. Key Countries/Regions Varicella Attenuated Live Vaccine Sales Volume, (2025-2030) & (K Doses)
Table 57. Merck Company Information
Table 58. Merck Introduction and Business Overview
Table 59. Merck Varicella Attenuated Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 60. Merck Varicella Attenuated Live Vaccine Product Offerings
Table 61. Merck Recent Development
Table 62. BCHT Company Information
Table 63. BCHT Introduction and Business Overview
Table 64. BCHT Varicella Attenuated Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 65. BCHT Varicella Attenuated Live Vaccine Product Offerings
Table 66. BCHT Recent Development
Table 67. Shanghai Institute Company Information
Table 68. Shanghai Institute Introduction and Business Overview
Table 69. Shanghai Institute Varicella Attenuated Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 70. Shanghai Institute Varicella Attenuated Live Vaccine Product Offerings
Table 71. Shanghai Institute Recent Development
Table 72. GSK Company Information
Table 73. GSK Introduction and Business Overview
Table 74. GSK Varicella Attenuated Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 75. GSK Varicella Attenuated Live Vaccine Product Offerings
Table 76. GSK Recent Development
Table 77. Keygen Company Information
Table 78. Keygen Introduction and Business Overview
Table 79. Keygen Varicella Attenuated Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 80. Keygen Varicella Attenuated Live Vaccine Product Offerings
Table 81. Keygen Recent Development
Table 82. Green Cross Company Information
Table 83. Green Cross Introduction and Business Overview
Table 84. Green Cross Varicella Attenuated Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 85. Green Cross Varicella Attenuated Live Vaccine Product Offerings
Table 86. Green Cross Recent Development
Table 87. Biken Company Information
Table 88. Biken Introduction and Business Overview
Table 89. Biken Varicella Attenuated Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 90. Biken Varicella Attenuated Live Vaccine Product Offerings
Table 91. Biken Recent Development
Table 92. Shanghai Rongsheng Biotech Company Information
Table 93. Shanghai Rongsheng Biotech Introduction and Business Overview
Table 94. Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 95. Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccine Product Offerings
Table 96. Shanghai Rongsheng Biotech Recent Development
Table 97. Changchun Changsheng Life Sciences Limited Company Information
Table 98. Changchun Changsheng Life Sciences Limited Introduction and Business Overview
Table 99. Changchun Changsheng Life Sciences Limited Varicella Attenuated Live Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 100. Changchun Changsheng Life Sciences Limited Varicella Attenuated Live Vaccine Product Offerings
Table 101. Changchun Changsheng Life Sciences Limited Recent Development
Table 102. Key Raw Materials Lists
Table 103. Raw Materials Key Suppliers Lists
Table 104. Varicella Attenuated Live Vaccine Downstream Customers
Table 105. Varicella Attenuated Live Vaccine Distributors List
Table 106. Research Programs/Design for This Report
Table 107. Key Data Information from Secondary Sources
Table 108. Key Data Information from Primary Sources
List of Figures
Figure 1. Varicella Attenuated Live Vaccine Product Picture
Figure 2. Global Varicella Attenuated Live Vaccine Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Varicella Attenuated Live Vaccine Sales Value (2019-2030) & (US$ Million)
Figure 4. Global Varicella Attenuated Live Vaccine Sales Volume (2019-2030) & (K Doses)
Figure 5. Global Varicella Attenuated Live Vaccine Sales Price (2019-2030) & (USD/Dose)
Figure 6. Varicella Attenuated Live Vaccine Report Years Considered
Figure 7. Global Varicella Attenuated Live Vaccine Players Revenue Ranking (2023) & (US$ Million)
Figure 8. Global Varicella Attenuated Live Vaccine Players Sales Volume Ranking (2023) & (K Doses)
Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Varicella Attenuated Live Vaccine Revenue in 2023
Figure 10. Varicella Attenuated Live Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 11. Monovalent Vaccine Picture
Figure 12. Combination Vaccine Picture
Figure 13. Global Varicella Attenuated Live Vaccine Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 14. Global Varicella Attenuated Live Vaccine Sales Value Market Share by Type, 2023 & 2030
Figure 15. Global Varicella Attenuated Live Vaccine Sales Volume by Type (2019 VS 2023 VS 2030) & (K Doses)
Figure 16. Global Varicella Attenuated Live Vaccine Sales Volume Market Share by Type, 2023 & 2030
Figure 17. Global Varicella Attenuated Live Vaccine Price by Type (2019-2030) & (USD/Dose)
Figure 18. Product Picture of Kids Injection
Figure 19. Product Picture of Adults Injection
Figure 20. Global Varicella Attenuated Live Vaccine Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 21. Global Varicella Attenuated Live Vaccine Sales Value Market Share by Application, 2023 & 2030
Figure 22. Global Varicella Attenuated Live Vaccine Sales Volume by Application (2019 VS 2023 VS 2030) & (K Doses)
Figure 23. Global Varicella Attenuated Live Vaccine Sales Volume Market Share by Application, 2023 & 2030
Figure 24. Global Varicella Attenuated Live Vaccine Price by Application (2019-2030) & (USD/Dose)
Figure 25. North America Varicella Attenuated Live Vaccine Sales Value (2019-2030) & (US$ Million)
Figure 26. North America Varicella Attenuated Live Vaccine Sales Value by Country (%), 2023 VS 2030
Figure 27. Europe Varicella Attenuated Live Vaccine Sales Value (2019-2030) & (US$ Million)
Figure 28. Europe Varicella Attenuated Live Vaccine Sales Value by Country (%), 2023 VS 2030
Figure 29. Asia Pacific Varicella Attenuated Live Vaccine Sales Value (2019-2030) & (US$ Million)
Figure 30. Asia Pacific Varicella Attenuated Live Vaccine Sales Value by Country (%), 2023 VS 2030
Figure 31. South America Varicella Attenuated Live Vaccine Sales Value (2019-2030) & (US$ Million)
Figure 32. South America Varicella Attenuated Live Vaccine Sales Value by Country (%), 2023 VS 2030
Figure 33. Middle East & Africa Varicella Attenuated Live Vaccine Sales Value (2019-2030) & (US$ Million)
Figure 34. Middle East & Africa Varicella Attenuated Live Vaccine Sales Value by Country (%), 2023 VS 2030
Figure 35. Key Countries/Regions Varicella Attenuated Live Vaccine Sales Value (%), (2019-2030)
Figure 36. Key Countries/Regions Varicella Attenuated Live Vaccine Sales Volume (%), (2019-2030)
Figure 37. United States Varicella Attenuated Live Vaccine Sales Value, (2019-2030) & (US$ Million)
Figure 38. United States Varicella Attenuated Live Vaccine Sales Value by Type (%), 2023 VS 2030
Figure 39. United States Varicella Attenuated Live Vaccine Sales Value by Application (%), 2023 VS 2030
Figure 40. Europe Varicella Attenuated Live Vaccine Sales Value, (2019-2030) & (US$ Million)
Figure 41. Europe Varicella Attenuated Live Vaccine Sales Value by Type (%), 2023 VS 2030
Figure 42. Europe Varicella Attenuated Live Vaccine Sales Value by Application (%), 2023 VS 2030
Figure 43. China Varicella Attenuated Live Vaccine Sales Value, (2019-2030) & (US$ Million)
Figure 44. China Varicella Attenuated Live Vaccine Sales Value by Type (%), 2023 VS 2030
Figure 45. China Varicella Attenuated Live Vaccine Sales Value by Application (%), 2023 VS 2030
Figure 46. Japan Varicella Attenuated Live Vaccine Sales Value, (2019-2030) & (US$ Million)
Figure 47. Japan Varicella Attenuated Live Vaccine Sales Value by Type (%), 2023 VS 2030
Figure 48. Japan Varicella Attenuated Live Vaccine Sales Value by Application (%), 2023 VS 2030
Figure 49. South Korea Varicella Attenuated Live Vaccine Sales Value, (2019-2030) & (US$ Million)
Figure 50. South Korea Varicella Attenuated Live Vaccine Sales Value by Type (%), 2023 VS 2030
Figure 51. South Korea Varicella Attenuated Live Vaccine Sales Value by Application (%), 2023 VS 2030
Figure 52. Southeast Asia Varicella Attenuated Live Vaccine Sales Value, (2019-2030) & (US$ Million)
Figure 53. Southeast Asia Varicella Attenuated Live Vaccine Sales Value by Type (%), 2023 VS 2030
Figure 54. Southeast Asia Varicella Attenuated Live Vaccine Sales Value by Application (%), 2023 VS 2030
Figure 55. India Varicella Attenuated Live Vaccine Sales Value, (2019-2030) & (US$ Million)
Figure 56. India Varicella Attenuated Live Vaccine Sales Value by Type (%), 2023 VS 2030
Figure 57. India Varicella Attenuated Live Vaccine Sales Value by Application (%), 2023 VS 2030
Figure 58. Varicella Attenuated Live Vaccine Industrial Chain
Figure 59. Varicella Attenuated Live Vaccine Manufacturing Cost Structure
Figure 60. Channels of Distribution (Direct Sales, and Distribution)
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
